Open access · CC-BY
via OpenAlex
Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Isaac G. Onyango, Jameel Dennis, Shaharyah M. Khan
Aging and Disease · 2016 · ▲ 259 citations
Abstract
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder characterized by the progressive loss of cholinergic neurons, leading to the onset of severe behavioral, motor and cognitive impairments. It is a pressing public health problem with no effective treatment. Existing therapies only provide symptomatic relief without being able to prevent, stop or reverse the pathologic process. While the molecular basis underlying this multifactorial neurodegenerative disorder remains a significant challenge, mitochondrial dysfunction(definition) appears to be a critical factor in the pathogenesis of this disease. It is therefore important to target mitochondrial dysfunction in the prodromal phase of AD to slow or prevent the neurodegenerative process and restore neuronal function. In this review, we discuss mechanisms of action and translational potential of current mitochondrial and bioenergetic therapeutics for AD including: mitochondrial enhancers to potentiate energy production; antioxidants to scavenge reactive oxygen species and reduce oxidative damage; glucose metabolism and substrate supply; and candidates that target apoptotic and mitophagy pathways to remove damaged mitochondria. While mitochondrial therapeutic strategies have shown promise at the preclinical stage, there has been little progress in clinical trials thus far.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.14336/ad.2015.1007
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Onyango, I.G., Dennis, J., & Khan, S.M. (2016). Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies. <em>Aging and Disease</em>. https://doi.org/10.14336/ad.2015.1007
Vancouver
Onyango IG, Dennis J, Khan SM. Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies. Aging and Disease. 2016. doi:10.14336/ad.2015.1007.
BibTeX
@article{isaac2016Mitoch,
title = {Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies},
author = {Isaac G. Onyango and Jameel Dennis and Shaharyah M. Khan},
journal = {Aging and Disease},
year = {2016},
doi = {10.14336/ad.2015.1007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Alzheimer s Disease 2017
Open access · OA
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
European Neuropsychopharmacology 2019
Citation only
MITOCHONDRIAL DYSFUNCTION IN ALZHEIMER'S DISEASE
Neural Regeneration Research 2018
Open access · OA
Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease
Molecular Neurodegeneration 2023
Open access · CC-BY
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Current Neuropharmacology 2024
Preprint · CC-BY
Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer’s Disease: Recent Advances and Therapeutic Implications
npj Aging 2026
Open access · CC-BY